Hundreds of biotech CEOs delivered a letter to FDA Director Marty Makary warning that regulatory unpredictability threatens innovation; the group cited survey evidence that 82% of respondents were concerned about FDA function. The letter asks for predictable, science‑based regulatory processes to sustain U.S. biotech investment and development. Separately, an aide closely associated with Commissioner Makary who had clashed with the White House will remain at the FDA but will not be promoted. The episode underscores industry anxieties about political influence at the agency and prompted public calls from companies and lawmakers for clearer, career‑staff‑led decision making.